Cantor Fitzgerald Analyzed Genesis Healthcare (GEN) with $7 Target, Huff W R Asset Management Company Boosted By $1.19 Million Its Teva Pharmaceutical (TEVA) Holding

July 6, 2017 - By Henry Gaston

Huff W R Asset Management Company Llc increased Teva Pharmaceutical (TEVA) stake by 134.4% reported in 2016Q4 SEC filing. Huff W R Asset Management Company Llc acquired 33,082 shares as Teva Pharmaceutical (TEVA)’s stock declined 15.11%. The Huff W R Asset Management Company Llc holds 57,697 shares with $2.09 million value, up from 24,615 last quarter. Teva Pharmaceutical now has $33.45 billion valuation. The stock decreased 1.80% or $0.6 during the last trading session, reaching $32.71. About 630 shares traded. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since July 6, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Among 4 analysts covering Genesis Healthcare (NYSE:GEN), 0 have Buy rating, 2 Sell and 2 Hold. Therefore 0 are positive. Genesis Healthcare has $10.0 highest and $1.50 lowest target. $2.58’s average target is 57.32% above currents $1.64 stock price. Genesis Healthcare had 9 analyst reports since August 10, 2015 according to SRatingsIntel. RBC Capital Markets maintained Genesis Healthcare Inc (NYSE:GEN) on Tuesday, January 26 with “Outperform” rating. UBS maintained it with “Neutral” rating and $5.50 target in Monday, November 9 report. Susquehanna maintained the stock with “Neutral” rating in Tuesday, January 26 report. RBC Capital Markets maintained it with “Outperform” rating and $3 target in Monday, May 16 report. The company was downgraded on Tuesday, January 26 by Bank of America. As per Monday, February 8, the company rating was downgraded by UBS. On Monday, August 10 the stock rating was upgraded by RBC Capital Markets to “Sector Perform”. Bank of America downgraded the stock to “Underperform” rating in Monday, May 16 report. The company was downgraded on Monday, November 21 by RBC Capital Markets.

The stock decreased 7.34% or $0.13 during the last trading session, reaching $1.64. About shares traded. Genesis Healthcare Inc (NYSE:GEN) has risen 29.94% since July 6, 2016 and is uptrending. It has outperformed by 13.24% the S&P500.

Genesis Healthcare, Inc. is a holding firm that provides post-acute care. The company has market cap of $257.80 million. The Firm operates through three divisions: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. It currently has negative earnings. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities.

Among 25 analysts covering Teva Pharma (NYSE:TEVA), 13 have Buy rating, 0 Sell and 12 Hold. Therefore 52% are positive. Teva Pharma had 60 analyst reports since July 21, 2015 according to SRatingsIntel. On Tuesday, July 21 the stock rating was maintained by Leerink Swann with “Outperform”. Cowen & Co maintained it with “Outperform” rating and $50 target in Wednesday, April 5 report. The stock has “Buy” rating by Deutsche Bank on Wednesday, November 16. Barclays Capital maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Tuesday, January 31 with “Equal Weight” rating. The rating was downgraded by JP Morgan to “Neutral” on Friday, January 20. The stock has “Buy” rating by Maxim Group on Wednesday, January 4. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Neutral” rating given on Friday, February 10 by Mizuho. The firm has “Buy” rating given on Tuesday, July 28 by Argus Research. The firm earned “Outperform” rating on Wednesday, December 7 by Oppenheimer. Oppenheimer maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Friday, April 7 with “Buy” rating.